Stryker Corp. is under investigation by Pomerantz LLP following the CEO's announcement that a manufacturing problem affecting its peripheral vascular inventory, initially expected to be resolved in Q3 2026, will now continue into Q4. This revelation caused Stryker's stock to fall by 8.81% on September 8, 2026. The investigation is examining whether the company and its officers engaged in securities fraud or other unlawful practices. Investors affected are encouraged to contact the law firm for potential class action participation.
Stryker Corporation shares trade at USD 274.03 on Pluang as of Oct 08, 2026 21:12 WIB, down 0.50% in one day. The stock's market cap stands at $105.64 billion with a dividend yield of 1.28%. Pluang users show strong buying interest with 100% buy orders and a typical hold time of 20 days.
Stryker experienced an 8.8% stock drop on September 8, 2026, wiping out over $10 billion in market value due to ongoing manufacturing problems that were thought resolved. Truist Financial lowered its price target from $340 to $310, reflecting concern...
Stryker (SYK) has been upgraded to a 'Strong Buy' following a significant price pullback to $275, presenting attractive value compared to its historical valuation. The company shows robust organic sales growth across various regions and segments, dri...
